Your browser doesn't support javascript.
loading
Systematic literature review of traits and outcomes reported in randomised controlled trials of asthma with regular dosing of inhaled corticosteroids with short-acting ß2-agonist reliever, as-needed ICS/formoterol, or ICS/formoterol maintenance and reliever therapy.
Roche, Nicolas; Yorgancioglu, Arzu; Cruz, Alvaro A; Garcia, Gabriel; Lavoie, Kim L; Abhijith, P G; Verma, Manish; Majumdar, Anurita; Chatterjee, Swarnendu.
Afiliación
  • Roche N; Pneumology, AP-HP Centre Université Paris Cité, Hôpital Cochin, Paris, France.
  • Yorgancioglu A; Department of Pulmonology, Celal Bayar University, Manisa, Turkey.
  • Cruz AA; ProAR and Universidade Federal da Bahia, Salvador, Brazil.
  • Garcia G; Respiratory Research Center, CEPIR, La Plata, Argentina.
  • Lavoie KL; University of Quebec at Montreal (UQAM), Montreal, Canada; Montreal Behavioural Medicine Centre, CIUSSS-NIM, Hopital du Sacre-Coeur de Montreal, Montreal, Canada.
  • Abhijith PG; GSK, Global Medical Affairs, General Medicine, Amsterdam, the Netherlands.
  • Verma M; GSK, Global Medical Affairs, General Medicine, Mumbai, India. Electronic address: manish.8.verma@gsk.com.
  • Majumdar A; GSK, Global Medical Affairs, General Medicine, Singapore.
  • Chatterjee S; GSK, Hyderabad, Telangana, India.
Respir Med ; 221: 107478, 2024 Jan.
Article en En | MEDLINE | ID: mdl-38008385
INTRODUCTION: Asthma treatments based solely on diagnostic label do not benefit patients equally. To identify patient traits that may be associated with improved treatment response to regular inhaled corticosteroid (ICSs) dosing with short-acting ß2-agonist reliever or ICS/formoterol-containing therapy, a systematic literature review (SLR) was conducted. METHODS: Searches of databases including MEDLINE and Embase identified randomised controlled trials (RCTs) of patients with asthma, aged ≥12 years, published 1998-2022, containing ≥1 regular ICS dosing or ICS/formoterol-containing treatment arm, and reporting patient traits and outcomes of interest. Relevant data was extracted and underwent a feasibility assessment to determine suitability for meta-analysis. RESULTS: The SLR identified 39 RCTs of 72,740 patients and 90 treatment arms, reporting 11 traits and 11 outcomes. Five patient traits (age, body mass index, FEV1, smoking history, asthma control) and five outcomes (exacerbation rate, lung function, asthma control, adherence, time to first exacerbation) were deemed feasible for inclusion in meta-analyses due to sufficient comparable reporting. Subgroups of clinical outcomes stratified by levels of patient traits were reported in 16 RCTs. CONCLUSION: A systematic review of studies of regular ICS dosing with SABA or ICS/formoterol-containing treatment strategies in asthma identified consistent reporting of five traits and outcomes, allowing exploration of associations with treatment response. Conversely, many other traits and outcomes, although being potentially relevant, were inconsistently reported and limited subgroup reporting meant analyses of treatment response for subgroups of traits was not possible. We recommend more consistent measurement and reporting of clinically relevant patient traits and outcomes in respiratory RCTs.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Asma / Antiasmáticos Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: Respir Med Año: 2024 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Asma / Antiasmáticos Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: Respir Med Año: 2024 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido